Oncothyreon, Sentinel Oncology Agreement Worth Up to $174M

Apr 23, 2014


Small molecule drug discoverer Sentinel Oncology has made an agreement with Oncothyreon toward developing Sentinel’s Checkpoint Kinase 1 (Chk1) program under which Oncothyreon will fund additional research done at Sentinel toward discovering therapeutics directed at the Chk1 target. The cancer-focused company is also receiving the rights to develop and commercialize any of the compounds that result from Sentinel's research. Sentinel could receive up to $174 million in preclinical, clinical, and commercial milestone payments as part of this agreement, plus any royalties on net sales. Read the full story

Join the discussion

We welcome your thoughtful comments. Please comply with our Community rules.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments